Abstract. The activity of CB 1 cannabinoid receptors was studied in postmortem brain samples of Alzheimer's disease (AD) patients during clinical deterioration. CB 1 activity was higher at earlier AD stages in limited hippocampal areas and internal layers of frontal cortex, but a decrease was observed at the advanced stages. The pattern of modification appears to indicate initial hyperactivity of the endocannabinoid system in brain areas that lack classical histopathological markers at earlier stages of AD, indicating an attempt to compensate for the initial synaptic impairment, which is then surpassed by disease progression. These results suggest that initial CB 1 stimulation might have therapeutic relevance.
INTRODUCTION
The decline in synaptic function appears at early stages of Alzheimer's disease (AD), which correlates with cognitive dysfunction in AD patients [1, 2] at areas innervated by the cholinergic cells of the basal forebrain [3, 4] . The neuropathological markers, used for the classification of AD patients in different stages, have been found in subjects without dementia that may represent a preclinical stage of the illness [5] . * Correspondence to: Rafael Rodríguez-Puertas, Department of Pharmacology, Faculty of Medicine and Odontology, University of the Basque Country, E-48940, Leioa, Vizcaya, Spain. Tel.: +34 94 6012739; Fax: +34 94 6013220; E-mail: rafael.rodriguez@ehu.es.
The study of the endocannabinoid synapse is particularly interesting with regard to AD because cannabinoid receptor expression and other components of the endocannabinoid system have been found to be modified [6] . Reduction of CB 1 receptor density has been described in the hippocampus and caudateputamen [7] . The localization of the cannabinoid receptors in the brain suggests its involvement in the modulation of learning and memory [8] . Some cannabinoid compounds are able to induce amnesia and memory deficits in mice [9] and regulate fearconditioned memory [10] . In addition, increase in cannabinoid tone appears to induce neuronal survival [11] . The genetic deletion of CB 1 receptors induces neuronal loss in the hippocampus, accompanied by a decline in cognitive functions [12] . Therefore, the activity mediated by CB 1 receptors might regulate some cognitive functions and neuroprotective actions.
In the present study, we analyze the activity and density of CB 1 cannabinoid receptors in postmortem tissue from patients during AD progression.
MATERIALS AND METHODS
Brain tissue samples from 17 control cases and 36 AD patients were obtained from the tissue bank of the Hospital of Bellvitge, Barcelona. The AD patients were divided into three groups according to Braak's stages [13, 14] , and were matched for age, postmortem delay, and freezing storage time.
Tissue sections were incubated with 0. The activity of CB 1 receptors was lower during AD stages V-VI than during stages I-II in the pyramidal and radiatum layers of the hippocampal CA1. The increased activity measured in the AD I-II group compared with the control group was partially responsible for this significant effect. This increase was statistically significant in the hilus of the dentate gyrus during stages I-II and decreased during stages V-VI. At stages III-IV, the CB 1 activity was similar to the control group in most of the hippocampal areas (Supplementary Fig. 1 ). The increased activity at stages I-II might be delaying the deterioration of CB 1 -mediated activity. In contrast, in the lateral nucleus of the amygdala, CB 1 -mediated activity decreased from the initial stages of the disease. In the nbM and striatal areas, CB 1 activity was not altered in AD.
We quantified the cannabinoid receptor density by measuring the specific labeling of the radioligand [ 3 H]CP55,940 ( Table 2 ). The CB 1 cannabinoid receptors were upregulated in layer VI of the frontal cortex in patients with stage III-IV AD. In the hippocampus, CB 1 receptor density was altered in different hippocampal subfields in AD patients depending on the AD stage. Receptor density was increased relative to control cases mainly during AD stages III-IV. The density of receptors decreased to or fell below control levels at the most advanced stages ( Supplementary  Fig. 1 ). In the amygdala, CB 1 density was very low, and the measured densities of cannabinoid receptors were maintained during disease progression. Cannabinoid receptor density was not altered in the nbM of AD patients. In the caudate-putamen, the CB 1 receptor density increased during the initial stages of AD compared with control densities and a trend to decrease to control levels was observed during the next stages.
DISCUSSION
The aim of the present study was to analyze the status of the endocannabinoid system during AD progression. Patients were divided in three groups according to Braak's neuropathological stages (stages I-II, III-IV, and V-VI) [13, 15] . We observed regulation of the activation of the signaling cascade by G i/o proteins mediated through cannabinoid receptors during AD progression. The data obtained from the [ 3 H]CP55,940 autoradiography did not correlate with the WIN55,212-2-stimulated binding. Therefore, receptor density and receptor efficiency are modulated separately. The different lipid composition of the neuronal membranes can modulate the CB 1 activity [16] .
The frontal cortex tissue sections from AD patients exhibit an apparent increase of the CB 1 activity in the AD I-II stages compared to AD III-IV. Previous studies that analyzed CB 1 receptor density and expression in cortical areas did not describe changes in AD [7, 17] , but other binding and PET studies showed that CB 1 densities were reduced in frontal cortex [6, 18, 19] . The increase of CB 1 receptor activity that we observed during the initial stages of AD might indicate a neuroprotective action mediated by endocannabinoids in response to initial neural damage, which has been extensively reviewed [20] . Analysis of the [ 3 H]CP55,940 binding sites during disease progression revealed a significant increase of CB 1 receptor density at layer VI of the frontal cortex in the AD III-IV patient group. The results indicate that the regulation of CB 1 -mediated activity precedes the increase in receptor density. The increased efficiency could be less metabolically costly to the cell than the increased availability of new receptors. Recent studies have reported a reduction in the enzyme responsible for the synthesis of anandamide in the cortex of AD patients [21] . The regulation of the CB 1 density and activity that we describe at cortex might be a compensatory mechanism to balance the anandamide signaling.
In a previous study CB 1 receptor density has been found decreased at the hippocampus in AD patients [7] . But when we analyzed it in detail during the progression of the disease, the CB 1 activation was greater during AD stages I-II, decreased to levels similar to the control group during AD stages III-IV, and continued to fall below control group levels during AD stages V-VI. These effects were significant at the pyramidal layers and the dentate gyrus, areas in which the cannabinoid receptors are more densely located at synaptic terminals. Therefore, the increase of activity 764 (n = 4-6) (n = 6) (n = 7) (n = 4-5) Granular 80.2 ± 10.1 95.8 ± 3.5 99.5 ± 8.5 70.8 ± 8.5 * ,c Hilus 64.3 ± 9.9 67.7 ± 6.3 74.6 ± 6.6 65.2 ± 5.6 Subiculum (n = 5-7) (n = 6-7) (n = 5-6) (n = 6) Lacunosum moleculare 44.6 ± 6.5 46.4 ± 7.5 64. during AD stages I-II might be an initial response to neural impairment. Moreover, an increase of monoacylglycerol lipase activity has been described in AD stages V-VI that might contribute to the accumulation of 2-arachidonoyl glycerol, resulting in synaptic failure with the consequent downregulation of CB 1 receptors [22] . However, immunohistochemical assays have described no changes in CB 1 receptors [23] .
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We observed that the regulation on CB 1 densities was delayed during the advance of AD compared with the modulation of CB 1 activity. The [ 3 H]CP55,940 binding sites were decreased at later stages in the pyramidal layers of different hippocampal areas and the inner layers of the entorhinal cortex.
The nbM cholinergic cells innervate the amygdala, where the functional CB 1 receptors decreased in the lateral nucleus of the amygdala in AD patients. In contrast, the number and expression of cannabinoid receptors in the human amygdala are low [24, 7] . We also observed low CB 1 receptor density in the amygdala, which was conserved in AD patients. This finding suggests that the down-regulation of cannabinoid activity is not indicating modulation in receptor density. On the contrary, CB 1 activity in the striatal area was conserved in AD patients, but CB 1 density was high and was increased at the initial AD stages, continuing to a reduction with the progression of the disease, which might be caused by the loss of afferents from areas such as the globus pallidus and the substantia nigra, where a reduction of CB 1 of receptors had been reported [7] . Although the incidence of co-morbidity with parkinsonism is frequent in AD patients, we were unaware if this was the case in any of the cases included in the present study. In addition, maintained levels of CB 1 cannabinoid receptors have been described in Parkinson's disease [25] .
In summary, CB 1 receptors were more efficient in the patients at the earlier AD stages, specifically in hippocampal areas. These regulations on CB 1 signaling might precede to the accumulation of the neuropathological markers of the AD in specific brain areas. On the contrary, at the most advanced stages of AD, CB 1 efficacy diminished in both the hippocampus and the frontal cortex. The modulation of CB 1 density follows the same pattern, but occurs later in the course of AD.
The initial hyperactivity of the endocannabinoid system accounts for the possible compensation of synaptic impairment; however, the intimate and unknown cause of AD continues with neurodegeneration and determines a loss of CB 1 synapses. CB 1 stimulation might have therapeutic relevance during the initial and moderate stages of AD.
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